Vaccinex

Biotechnology, Clinical Trials, Health Care
Founded in 1/1/97
Rochester, New York, United States
http://www.vaccinex.com/
For Profit

About Vaccinex

Vaccinex has developed an antibody discovery platform that enables efficient mammalian cell-based expression for expression of large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface envelope of a mammalian virus and the cell surface membrane of the infected cell. This allows them to combine the advantages of virus panning and cell sorting into one seamless selection process. This technology enables the rapid selection of 1010 antibody combinations and thus selection of high affinity leads with varied frameworks that recognize multiple epitopes. It is based in Rochester, New York.

Company Metrics

  • Employees: 11-50
  • Monthly Visits: 2194
  • Tech Stack: 6 active products

Financial Information

  • Estimated Revenue: Less than $1M
  • Total Funding: 65899915 USD
  • Last Funding: 6600000 USD (Post-IPO Equity)
  • Funding Status: IPO

Technology Stack

Vaccinex actively uses 6 products in their tech stack.

Market Presence

Industries: Biotechnology, Clinical Trials, Health Care

Headquarters: Rochester, New York, United States